Fate Therapeutics
FATE
23 hedge funds and large institutions have $51.7M invested in Fate Therapeutics in 2014 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 10 increasing their positions, 4 reducing their positions, and 2 closing their positions.
150% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 4
100% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 2
5% more funds holding
Funds holding: 22 → 23 (+1)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.14% less ownership
Funds ownership: 49.93% → 49.79% (-0.14%)
2% less capital invested
Capital invested by funds: $52.6M → $51.7M (-$900K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KCM
Kingdon Capital Management
New York
|
+$558K |
| 2 |
HCMT
Highland Capital Management (Texas)
Dallas,
Texas
|
+$147K |
| 3 |
Alyeska Investment Group
Chicago,
Illinois
|
+$110K |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$34.4K |
| 5 |
Principal Financial Group
Des Moines,
Iowa
|
+$20.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$880K |
| 2 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
-$74.2K |
| 3 |
Goldman Sachs
New York
|
-$45.3K |
| 4 |
Morgan Stanley
New York
|
-$22.9K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$5.51K |
FATE Hedge Fund Activity: Q4 2014 in Review
23 of the 3,765 institutional investors tracked by Wall St. Rank reported a position in Fate Therapeutics (FATE) for Q4 2014, worth a combined $51.7M — down 1.7% from $52.6M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new FATE positions and 2 closed out — a net gain of 2 holders — while 10 added to existing stakes and 4 trimmed.
The largest buyer was Kingdon Capital Management, adding an estimated $558K. The largest seller was Farallon Capital Management, exiting entirely with an estimated $880K sold.
- 23 institutional investors held Fate Therapeutics (FATE) as of Q4 2014, up from 22 in Q3 2014.
- Funds reported $51.7M of Fate Therapeutics stock for Q4 2014, down 1.7% quarter-over-quarter.
- 4 funds opened new Fate Therapeutics positions in Q4 2014 and 2 closed out, a net change of +2 holders.
- The largest Fate Therapeutics buyer in Q4 2014 was Kingdon Capital Management, an estimated $558K added.
- The largest Fate Therapeutics seller in Q4 2014 was Farallon Capital Management, an estimated $880K sold.
Based on aggregated 13F filings for Q4 2014.